Justin Taylor, MD

Justin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.

Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.